|
시장보고서
상품코드
2091551
갱년기 안면 홍조 시장 규모, 점유율, 성장 분석 : 치료법별, 약물 계열별, 투여 경로별, 중증도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Menopausal Hot Flashes Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Class, By Route of Administration, By Severity, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 갱년기 안면 홍조 시장 규모는 2024년에 88억 달러로 평가되었으며, 2025년 93억 4,000만 달러에서 2033년까지 149억 9,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 6.1%로 성장할 것으로 전망됩니다.
세계 갱년기 안면 홍조 시장은 갱년기를 맞이한 여성의 혈관운동 증상을 완화하는 것을 목적으로 하는 의약품, 영양보조식품 및 의료기기로 구성되어 있습니다. 여성의 약 80%가 안면 홍조로 고생하고 있는 만큼, 효과적인 치료법에 대한 수요는 매우 높습니다. 초기에는 호르몬 대체요법에 의존했으나, 호르몬 요법과 관련된 안전성 및 규제상의 우려로 인해 시장은 SSRI나 허브 제제 등의 비호르몬 요법으로 전환되고 있습니다. 이러한 비호르몬 치료에 대한 규제 당국의 태도가 점차 완화되고 있는 것은, 시장 진입 장벽을 낮추고 약물전달 기술의 혁신을 촉진함으로써 시장 성장을 뒷받침하고 있습니다. 또한, 규제 당국이 신규 신경조절제의 승인 절차를 신속화함에 따라, 제조사들은 임상시험을 신속하게 진행할 수 있게 되어 시장에 조기에 진출할 수 있는 길이 열리고 있습니다. 이는 아시아태평양 여성들의 병원 방문 횟수가 대폭 감소한 사실에서도 분명히 드러납니다.
세계 갱년기 안면 홍조 시장의 성장요인
세계 갱년기 안면 홍조 시장의 주요 성장 촉진요인 중 하나는, 여성 건강 문제에 대한 관심이 높아짐에 따라 여성들 사이에서 갱년기 증상에 대한 인식과 진단이 증가하고 있다는 점입니다. 갱년기를 맞이하는 여성이 늘어남에 따라, 흔한 증상인 안면 홍조에 대한 효과적인 치료법 및 관리법에 대한 수요가 높아지고 있습니다. 이러한 인식의 확산은 계몽 캠페인과 의료 자원의 이용 가능성 덕분에 더욱 가속화되고 있으며, 이에 따라 더 많은 여성들이 의료적 조언과 지원을 구하고 있습니다. 또한, 호르몬 대체요법이나 자연 요법 등 치료 옵션이 확대되고 있는 점도, 여성들이 자신의 증상을 관리하기 위한 맞춤형 해결책을 모색하는 가운데 시장 성장을 더욱 뒷받침하고 있습니다.
세계 갱년기 안면 홍조 시장의 제약요인
세계 갱년기 안면 홍조 시장의 주요 시장 억제요인 중 하나는 여성들 사이에서 대체 요법에 대한 인식이 높아지면서 이를 선호하는 경향이 나타나고 있다는 점입니다. 호르몬 대체요법(HRT)에 따른 잠재적인 부작용과 건강 위험에 대한 우려로 인해, 많은 여성들이 갱년기 증상 관리에 자연 요법, 생활 습관 개선, 비호르몬 치료를 점점 더 많이 선택하고 있습니다. 열감과 함께 나타나는 불편함을 완화하기 위해 소비자들이 더 안전하고 종합적인 대안을 모색하는 가운데, 이러한 대체 요법으로의 전환은 기존 의약품 솔루션의 성장을 제한할 가능성이 있습니다. 그 결과, 이 부문에서 기존 의약품에 의존해 온 기업들에게 이러한 동향은 과제가 되고 있습니다.
세계 갱년기 안면 홍조 시장의 동향
세계 갱년기 안면 홍조 시장에서는 맞춤형 호르몬 무첨가 치료법으로의 큰 전환이 진행되고 있으며, 이는 여성들의 맞춤형 치료법에 대한 수요가 증가하고 있음을 반영하고 있습니다. 이러한 추세는 개별 증상의 경향, 생활 방식 및 기존 건강 상태에 부합하는 비호르몬 요법에 대한 선호도가 높아지고 있음을 보여줍니다. 각 기업은 식물 유래 추출물, 신경계를 표적으로 하는 펩타이드, 그리고 유효성과 안전성을 최우선으로 한 새로운 투여 방법의 개발을 통해 이 분야에서 적극적으로 혁신을 추진하고 있습니다. 이러한 움직임은 업계 리더와 학술 기관 간의 협력을 촉진하여, 기존의 호르몬 요법에 수반되는 위험 없이 갱년기 증상을 관리할 수 있도록 특별히 설계된 틈새 제품의 등장으로 이어지고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 갱년기 안면 홍조 시장 규모 : 치료 유형별
세계의 갱년기 안면 홍조 시장 규모 : 약물 계열별
세계의 갱년기 안면 홍조 시장 규모 : 투여 경로별
세계의 갱년기 안면 홍조 시장 규모 : 중증도별
세계의 갱년기 안면 홍조 시장 규모 : 최종사용자별
세계의 갱년기 안면 홍조 시장 규모 : 유통 채널별
세계의 갱년기 안면 홍조 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.23Global Menopausal Hot Flashes Market size was valued at USD 8.8 Billion in 2024 and is poised to grow from USD 9.34 Billion in 2025 to USD 14.99 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).
The global market for menopausal hot flashes comprises pharmaceuticals, nutraceuticals, and devices aimed at alleviating vasomotor symptoms in women experiencing menopause. With approximately 80% of women facing hot flashes, the demand for effective treatments is substantial. Initially reliant on hormone replacement therapies, the market has shifted towards non-hormonal alternatives, such as SSRIs and herbal solutions, due to safety and regulatory concerns surrounding hormone therapies. The increasing regulatory openness towards these non-hormonal treatments fosters market growth by lowering entry barriers and driving innovation in drug delivery technologies. Furthermore, accelerated approvals for new neuromodulators by regulatory bodies empower manufacturers to conduct clinical trials swiftly, paving the way for prompt market entry, as evidenced by significant reductions in clinic visits among women in the Asia-Pacific region.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Menopausal Hot Flashes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Menopausal Hot Flashes Market Segments Analysis
Global menopausal hot flashes market is segmented by treatment type, drug class, route of administration, severity, end user, distribution channel and region. Based on treatment type, the market is segmented into Hormone Replacement Therapy (HRT), Non-Hormonal Drug Therapy, Complementary & Alternative Therapies and Lifestyle & Behavioral Interventions. Based on drug class, the market is segmented into Estrogen Therapy, Estrogen-Progestin Therapy, Neurokinin 3 (NK3) Receptor Antagonists, SSRIs & SNRIs and Others. Based on route of administration, the market is segmented into Oral, Transdermal, Injectable and Vaginal. Based on severity, the market is segmented into Mild Hot Flashes, Moderate Hot Flashes, and Severe Hot Flashes. Based on end user, the market is segmented into Hospitals, Gynecology Clinics, Specialty Menopause Centers and Homecare Settings. Based on distribution channels, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Menopausal Hot Flashes Market
One key market driver for the global menopausal hot flashes market is the increasing awareness and diagnosis of menopausal symptoms among women, coupled with the growing focus on women's health issues. As more women enter menopause, there is a rising demand for effective treatments and management options for hot flashes, which is a common symptom. This heightened awareness is fueled by educational campaigns and the availability of healthcare resources, leading to more women seeking medical advice and support. Additionally, the expanding portfolio of treatment options, including hormone replacement therapies and natural remedies, further propels market growth as women seek personalized solutions to manage their symptoms.
Restraints in the Global Menopausal Hot Flashes Market
One significant market restraint for the global menopausal hot flashes market is the rising awareness and preference for alternative therapies among women. Many individuals are increasingly opting for natural remedies, lifestyle changes, and non-hormonal treatments to manage menopausal symptoms, driven by concerns over potential side effects and health risks associated with hormone replacement therapies (HRT). This shift towards alternative approaches can limit the growth of conventional pharmaceutical solutions, as consumers seek safer and more holistic options to alleviate discomfort associated with hot flashes. Consequently, this trend poses challenges for companies reliant on traditional drug offerings in this segment.
Market Trends of the Global Menopausal Hot Flashes Market
The Global Menopausal Hot Flashes market is experiencing a significant shift toward personalized, hormone-free therapies, reflecting women's increasing demand for tailored treatment options. This trend highlights a growing preference for non-hormonal alternatives that align with individual symptom profiles, lifestyles, and existing health conditions. Companies are actively innovating in this space by developing botanically-based extracts, peptides targeting the nervous system, and novel delivery methods that prioritize efficacy and safety. This movement has fostered collaborations between industry leaders and academic institutions, leading to the emergence of niche products specifically designed to address menopausal symptoms without the risks associated with traditional hormone therapies.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Disease Epidemiology
Global Menopausal Hot Flashes Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Hormone Replacement Therapy (HRT)
- Non-Hormonal Drug Therapy
- Complementary & Alternative Therapies
- Lifestyle & Behavioral Interventions
Global Menopausal Hot Flashes Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Estrogen Therapy
- Estrogen-Progestin Therapy
- Neurokinin 3 (NK3) Receptor Antagonists
- SSRIs & SNRIs
- Others
Global Menopausal Hot Flashes Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Transdermal
- Injectable
- Vaginal
Global Menopausal Hot Flashes Market Size by Severity & CAGR (2026-2033)
- Market Overview
- Mild Hot Flashes
- Moderate Hot Flashes
- Severe Hot Flashes
Global Menopausal Hot Flashes Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Gynecology Clinics
- Specialty Menopause Centers
- Homecare Settings
Global Menopausal Hot Flashes Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Menopausal Hot Flashes Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Class, Route of Administration, Severity, End User, Distribution Channel)
- US
- Canada
- Europe (Treatment Type, Drug Class, Route of Administration, Severity, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Class, Route of Administration, Severity, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Class, Route of Administration, Severity, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Severity, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Theramex HQ UK Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organon & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gedeon Richter Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Besins Healthcare SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mayne Pharma Group Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck KGaA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mithra Pharmaceuticals SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferrer Internacional S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Duchesnay Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kowa Company, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Radius Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
